Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.

Blitshteyn S, Schofield JR, Haire N, Afrin LB

Open source

DOI
10.1080/08923973.2026.2731357
Published
2026 Sep 14
Container
Immunopharmacology and immunotoxicology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/08923973.2026.2731357,
  title = {Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.},
  author = {Blitshteyn S and Schofield JR and Haire N and Afrin LB},
  year = {2026},
  journal = {Immunopharmacology and immunotoxicology},
  doi = {10.1080/08923973.2026.2731357},
  url = {https://doi.org/10.1080/08923973.2026.2731357}
}

RIS

TY  - JOUR
TI  - Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.
AU  - Blitshteyn S
AU  - Schofield JR
AU  - Haire N
AU  - Afrin LB
PY  - 2026
JO  - Immunopharmacology and immunotoxicology
DO  - 10.1080/08923973.2026.2731357
UR  - https://doi.org/10.1080/08923973.2026.2731357
ER  - 

APA

S, B., JR, S., N, H., & LB, A. (2026). Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.. Immunopharmacology and immunotoxicology. https://doi.org/10.1080/08923973.2026.2731357

Source records